New hope for diabetic eyes: stronger dose may stop vision loss
NCT ID NCT07118670
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a higher dose (8mg) of aflibercept in 40 adults with proliferative diabetic retinopathy (PDR) who do not have swelling in the center of the retina. The goal is to see if this treatment can improve the severity of the disease and maintain vision over 96 weeks. Participants receive the drug by injection into the eye, and doctors monitor safety and effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROLIFERATIVE DIABETIC RETINOPATHY (PDR) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Retina Consultants of Texas
Bellaire, Texas, 77401, United States
-
Retina Consultants of Texas - Austin Retina Associates
Austin, Texas, 78705, United States
-
Retina Consultants of Texas - San Antonio
San Antonio, Texas, 78240, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.